CódigoEEN
RDRFR20240411008
Alta en la Red:
12/4/2024
Deadline:
31/7/2024
Tipo:
Búsqueda de socios
Descripción
French start-up has developed proprietary bioproduction cell lines that precision control glycosylation, which is used to design antibody therapeutics with superior function. The first target is preventing patient resistance to treatments for autoimmune diseases. They are looking for partners for EIC Transition.
Si desea más información sobre la oportunidad tecnológica, envíe un e-mail indicando la referencia a CONTACTO